YOLFTbeta
Scisparc Ltd

Scisparc Ltd

SPRC · NASDAQ · Healthcare / Biotechnology

0.3531USD-0.00 (-0.62%)

Price History

Full chart

Market Stats

Previous Close0.3553
Open0.3588
Day Range0.3452 – 0.37
52-Week Range2.98 – 54.63
Volume50.31K
Market Cap3.03M
P/E (TTM)0.05
Forward P/E0.00
EPS98.07
Dividend Yield0.00%
Beta2.44
50-Day Avg5.94
200-Day Avg7.01

About

SciSparc Ltd., a clinical-stage pharmaceutical company, develops drugs based on cannabinoid therapies. Its drug development programs include SCI-110 for the treatment of Tourette syndrome and Alzheimer's disease and agitation; SCI-210 for the treatment of autism spectrum disorder and status epilepticus; and CannAmide, an anti-inflammatory and chronic pain solution. The company sells hemp seed oil-based products and others. The company has an agreement with Procaps to develop and commercially manufacture SCI-110 and palmitoylethanolamide oral tablets CannAmide in softgel capsule form. It also has an agreement with The Israeli Medical Center for Alzheimer's to conduct a phase IIa clinical trial to evaluate the safety, tolerability, and efficacy of SCI-110 in patients with Alzheimer's disease and agitation; and a collaboration with Clearmind Medicine Inc. The company was formerly known as Therapix Biosciences Ltd. and changed its name to SciSparc Ltd. in January 2021. SciSparc Ltd. was incorporated in 2004 and is headquartered in Tel Aviv-Yafo, Israel.

Company Details

  • SectorHealthcare
  • IndustryBiotechnology
  • CEOMr. Amitai Weiss
  • Employees3
  • HeadquartersTower A, Tel Aviv-Yafo, Israel, 6971916, USA
  • Websitehttps://scisparc.com

Leadership

  • Mr. Amitai WeissPresident & Director · b. 1962
  • Dr. Adi Zuloff-Shani Ph.D.Chief Technologies Officer · b. 1967

Financials

Income Statement

Currency: USD2006-12-312007-12-312008-12-312009-12-312010-12-312011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue----1.65M------487.00K838.00K498.00K550.00K1.07M1.35M2.88M1.31M856.00K
Growth (%)------------+72.07%-40.57%+10.44%+94.36%+26.01%+113.73%-54.64%-34.46%
Cost of Revenue16.16K50.13K68.95K135.45K196.13K205.97K---3.09K-5.00K147.00K179.00K164.00K33.00K322.00K683.00K800.00K225.00K
Gross Profit-16.16K-50.13K-68.95K-135.45K1.45M-205.97K----3.09K-482.00K691.00K319.00K386.00K1.04M1.02M2.20M506.00K631.00K
Gross Margin----88.12%------98.97%82.46%64.06%70.18%96.91%76.10%76.28%38.74%73.71%
Operating Expense1.65M5.00M4.34M2.15M4.52M3.00M---2.55M-6.24M10.40M4.43M3.68M6.80M8.40M7.97M7.82M9.38M
Operating Income-1.67M-5.05M-4.41M-2.29M-3.07M-3.21M-3.49M-379.61K-1.78M-2.55M-2.00M-5.75M-9.71M-4.11M-3.29M-5.77M-7.38M-5.77M-7.32M-8.75M
Operating Margin-----185.86%-------1181.52%-1159.19%-824.90%-598.73%-539.57%-547.88%-200.52%-560.18%-1022.08%
EBITDA-1.71M-4.83M-3.57M-2.33M-3.24M-1.04M-3.36M105.00K-1.77M-2.56M-2.00M-6.24M-6.93M-3.73M-2.39M-5.74M-2.35M-5.31M-6.97M-12.32M
EBITDA Margin-----196.22%-------1281.11%-827.45%-749.40%-434.00%-537.32%-174.83%-184.58%-534.00%-1439.14%
Net Income-1.72M-4.88M-3.64M-2.57M-3.55M-3.72M-3.54M59.44K-1.85M-2.53M-1.99M-6.24M-8.52M-5.36M-3.51M-5.80M-2.59M-5.12M-6.28M-12.18M
Net Income Margin-----215.06%-------1282.14%-1017.06%-1076.71%-637.64%-542.66%-192.43%-177.91%-481.16%-1422.78%
R&D1.20M2.52M2.83M1.12M3.63M1.96M2.31M1.33M462.26K238.49K738.83K2.02M2.71M1.64M649.00K1.99M2.80M1.64M1.81M2.19M
R&D as % of Total Revenue----220.16%------414.17%323.39%329.12%118.00%186.16%208.09%57.00%138.97%255.37%
Interest Expense---99.55K114.94K-25.16K8.04K3.34K-1.30K5.00K123.00K568.00K25.00K12.00K36.00K9.00K30.00K11.00K
Interest Expense % of Total Revenue----6.96%------1.03%14.68%114.06%4.55%1.12%2.67%0.31%2.30%1.29%

Balance Sheet

Currency: USD2006-12-312007-12-312008-12-312009-12-312010-12-312011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets11.22M15.22M10.01M12.22M9.98M4.43M1.09M1.69M261.18K1.67M1.24M9.57M4.56M1.15M2.56M9.92M10.61M11.18M10.35M7.62M
Total Liabilities4.23M5.81M2.50M6.58M4.89M1.48M702.74K695.76K377.51K510.80K672.02K1.18M4.48M1.14M1.13M1.77M4.16M1.59M1.41M2.48M
Total Equity6.98M8.46M5.80M3.71M3.22M866.16K-1.99M1.06M-36.72K1.31M572.71K8.13M185.00K14.00K1.43M8.14M6.45M7.61M8.15M4.24M
Cash5.67M5.93M2.47M2.28M427.78K2.92M858.46K1.47M157.68K1.57M675.40K9.20M1.49M870.00K1.95M6.88M3.57M2.08M1.54M4.59M
Total Debt3.74M4.05M1.48M1.48M--------1.85M500.00K465.00K504.00K27.00K76.00K46.00K366.00K
Net Debt-1.93M-1.88M-983.32K-802.27K-427.78K-2.92M-858.46K-1.47M-157.68K-1.57M-675.40K-9.20M363.00K-370.00K-1.48M-6.37M-3.55M-2.00M-1.49M-4.22M

Cash Flow

Currency: USD2006-12-312007-12-312008-12-312009-12-312010-12-312011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow-1.46M-3.18M-3.22M-1.91M-3.77M-3.78M-3.95M-2.74M-1.89M-1.32M-1.48M-4.58M-7.13M-4.70M-4.31M-5.06M-7.92M-5.89M-5.10M-4.14M
Investing Cash Flow-660.24K5.83M-2.32M3.59M2.15M-38.57K-12.05K11.77K-94.76K-512.34-4.42K-53.00K-2.09M1.27M24.00K-70.00K-7.08M-1.11M-1.63M-1.40M
Financing Cash Flow673.26-1.42M6.30M578.99K547.92K1.81M1.37M3.37M826.67K2.74M563.87K13.18M1.54M2.80M5.36M10.06M11.70M5.50M6.19M8.59M
Capital Expenditure189.85K47.95K168.32K46.34K108.78K38.57K18.74K1.15K513.621.02K4.16K44.00K17.00K1.00K35.00K35.00K4.87M000
Free Cash Flow-1.65M-3.22M-3.39M-1.96M-3.88M-3.82M-3.97M-2.74M-1.89M-1.32M-1.48M-4.62M-7.15M-4.70M-4.31M-5.10M-12.79M-5.89M-5.10M-4.14M
Dividends Paid-------------0000000
FCF to OCF113.00%101.51%105.22%102.43%102.88%101.02%100.47%100.04%100.03%100.08%100.28%100.96%100.24%100.02%100.00%100.69%161.50%100.00%100.00%100.00%
Dividend Paid to FCF-------------0.00%0.00%0.00%0.00%0.00%0.00%0.00%

Earnings

Report DateDec 31, 2015Mar 22, 2016May 30, 2016Aug 10, 2016Nov 23, 2016Mar 31, 2017Jun 4, 2017Aug 10, 2017Nov 4, 2017Mar 31, 2018Apr 30, 2018Sep 30, 2018Nov 28, 2018May 15, 2019Sep 30, 2019Dec 31, 2019Mar 31, 2020Jun 30, 2020Sep 30, 2020Dec 31, 2020Mar 31, 2021Jun 30, 2021Nov 4, 2024Apr 24, 2025
EPS Estimate0.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.00
EPS Actual-39.07-37.21-43.55-37.35-27.59-28.00-84.00-0.04-0.02-28.00-0.01-38.95-0.01-0.01-17.91-17.91-14.00-14.00-1.50-1.50-0.70-0.70-1.70-6.20
Surprise------------------------
Timing-After-hoursAfter-hoursAfter-hoursAfter-hours-After-hoursPre-marketAfter-hours-After-hours-------------

Key Statistics & Ratios

Market Cap3.03M
Enterprise Value-1.29M
Trailing P/E0.05
Forward P/E0.00
Price / Sales140.43
Price / Book0.69
EPS98.07
Book Value11.60
Revenue (TTM)856.00K
Gross Profit (TTM)631.00K
EBITDA-8.53M
Profit Margin0.00%
Operating Margin-848.95%
Return on Equity-178.39%
Return on Assets-60.68%
Shares Outstanding580.97K
Shares Float553.65K
Beta2.44
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%

Ownership Breakdown

Institutions
9.38%
Insiders
0.00%
Retail / Other
90.62%

Top Institutional Holders

  • UBS Group AG
    3.15K0.55%
  • SBI Securities Co Ltd
    10.00%
  • SRS Capital Advisors Inc
    00.00%
  • Strategic Investment Solutions Inc
    00.00%
  • JustInvest LLC
    00.00%
  • XTX Topco Ltd
    00.00%

Stock Splits

  • Mar 4, 20261:9
  • Jul 3, 20251:21
  • Sep 28, 20231:26